Thrivent Financial for Lutherans Purchases 106,498 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Thrivent Financial for Lutherans lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 738.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,928 shares of the company’s stock after purchasing an additional 106,498 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.39% of Medpace worth $40,176,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Proficio Capital Partners LLC raised its stake in shares of Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after buying an additional 241,827 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Medpace in the fourth quarter worth about $78,144,000. Iron Triangle Partners LP bought a new position in Medpace during the third quarter worth about $64,371,000. GW&K Investment Management LLC lifted its stake in Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after purchasing an additional 133,379 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Stock Performance

Shares of MEDP stock opened at $327.47 on Thursday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a market capitalization of $9.98 billion, a PE ratio of 25.93, a PEG ratio of 3.81 and a beta of 1.47. The stock’s fifty day moving average is $338.95 and its 200-day moving average is $340.25.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.